HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS)
Chloe L Thio1, Eric C Seaberg, Richard Skolasky
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. cthio@jhmi.edu
Insights
Coinfection with HIV-1 and hepatitis B virus (HBV) significantly increases liver-related mortality, particularly in individuals with lower CD4+ counts. Comprehensive hepatitis B management is crucial for those with HIV-1.
Area of Science:
- Hepatology
- Infectious Diseases
- Public Health
Background:
- Coinfection with Human Immunodeficiency Virus type 1 (HIV-1) and Hepatitis B Virus (HBV) is prevalent.
- Long-term data on liver disease mortality in coinfected individuals are scarce.
- This study aimed to assess liver-related mortality in a cohort at risk for HIV-1 and HBV infections.
Purpose of the Study:
- To investigate the impact of HIV-1 and HBV coinfection on liver-related mortality.
- To identify risk factors associated with increased liver mortality in coinfected individuals.
Main Methods:
- A multicenter, prospective cohort study of 5293 men who have sex with men.
- Classification based on HIV-1 antibody status and Hepatitis B surface antigen (HBsAg) status.
- Mortality rates estimated using person-years and Poisson regression.
Main Results:
- Liver-related mortality rate was 1.1 per 1000 person-years.
- Mortality was significantly higher in individuals coinfected with HIV-1 and HBsAg (14.2/1000) compared to those with single infections.
- Higher mortality rates were observed in coinfected individuals with lower nadir CD4+ cell counts and after the introduction of highly active antiretroviral therapy (HAART).
Conclusions:
- HIV-1 and HBV coinfection poses a substantial risk for liver-related mortality.
- Low CD4+ nadir counts are associated with increased mortality in coinfected individuals.
- Emphasizes the need for prevention, early detection, and integrated management of Hepatitis B in HIV-1-infected populations.
Background:
Although coinfection with HIV-1 and hepatitis B virus (HBV) is common, few long-term studies on liver-disease mortality in coinfected people have been undertaken. Our aim was to examine liver-related mortality among people at risk for HIV-1 and HBV infections.
Methods:
We used data from a multicentre, prospective cohort study to classify 5293 men who had sex with men, according to their HIV-1 antibody status, ascertained semiannually, and their hepatitis-B surface antigen status (HBsAg), which we ascertained at baseline. Mortality rates were estimated in terms of person-years and Poisson regression methods were used to test for significance of relative risks.
Findings:
326 (6%) men were HBsAg positive, of whom 213 (65%) were HIV-1 positive. Of the 4967 HBsAg negative men, 2346 (47%) were infected with HIV-1. The liver-related mortality rate was 1.1/1000 person years, and was higher in men with HIV-1 and HBsAg (14.2/1000) than in those with only HIV-1 infection (1.7/1000, p<0.001) or only HBsAg (0.8/1000, p<0.001). In coinfected individuals, the liver-related mortality rate was highest with lower nadir CD4+ cell counts and was twice as high after 1996, when highly active antiretroviral therapy (HAART) was introduced.
Interpretation:
Individuals coinfected with HIV-1 and HBV, especially those with low CD4+ nadir counts, are at increased risk for liver-related mortality, underscoring the importance of prevention, identification, and comprehensive management of hepatitis B in people infected with HIV-1.
Related Concept Videos
Investigation of Disease Outbreaks
Arboviral Encephalitis
Yellow Fever
Cytomegalovirus Disease
Hepatitis


